Leonteq Securities’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$47.4K Buy
3,929
+640
+19% +$8K ﹤0.01% 789
2026
Q2
$55.6K Sell
3,289
-5,377
-62% -$75.3K ﹤0.01% 785
2026
Q1
$111K Sell
8,666
-48,124
-85% -$613K ﹤0.01% 706
2025
Q4
$511K Buy
56,790
+55,900
+6,281% +$770K 0.02% 455
2025
Q3
$15.4K Sell
890
-4,008
-82% -$49.4K ﹤0.01% 1069
2025
Q2
$45.9K Sell
4,898
-4,458
-48% -$36.6K ﹤0.01% 863
2025
Q1
$66.4K Buy
9,356
+9,265
+10,181% +$93.6K ﹤0.01% 792
2024
Q4
$1.06K Buy
91
+12
+15% +$187 ﹤0.01% 1186
2024
Q3
$1.62K Sell
79
-155
-66% -$3.57K ﹤0.01% 1107
2024
Q2
$5.24K Buy
234
+55
+31% +$1.31K ﹤0.01% 1042
2024
Q1
$4.92K Hold
179
– – ﹤0.01% 1082
2023
Q4
$5.46K Buy
179
+72
+67% +$2.07K ﹤0.01% 1052
2023
Q3
$3.38K Sell
107
-130
-55% -$5.04K ﹤0.01% 1104
2023
Q2
$9.7K Sell
237
-5,782
-96% -$234K ﹤0.01% 1049
2023
Q1
$224K Buy
6,019
+1,450
+32% +$56.9K 0.01% 499
2022
Q4
$159K Sell
4,569
-360
-7% -$17.1K 0.01% 586
2022
Q3
$276K Buy
4,929
+1,493
+43% +$92.6K 0.01% 466
2022
Q2
$178K Buy
3,436
+2,706
+371% +$137K 0.01% 577
2022
Q1
$53K Sell
730
-3,274
-82% -$277K ﹤0.01% 850
2021
Q4
$473K Buy
4,004
+1,636
+69% +$205K 0.02% 469
2021
Q3
$318K Buy
+2,368
New +$359K 0.01% 506

Other funds holding NTLA

Leonteq Securities's NTLA Position: Q3 2026 in Review

Leonteq Securities increased its Intellia Therapeutics (NTLA) stake by 19% in Q3 2026, buying an estimated $8K and bringing the position to 3,929 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Leonteq Securities first reported a position in NTLA in Q3 2021 and has held it in 21 quarters since. The position peaked at $511K in Q4 2025. 244 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Leonteq Securities held 3,929 shares of Intellia Therapeutics worth $47.4K as of Q3 2026.
  • Leonteq Securities bought 640 Intellia Therapeutics shares in Q3 2026, an estimated $8K.
  • Intellia Therapeutics made up ﹤0.01% of Leonteq Securities's portfolio in Q3 2026, its #789 holding.
  • Leonteq Securities first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 21 quarters since.
  • Leonteq Securities's Intellia Therapeutics position peaked at $511K in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Leonteq Securities's 13F filing for Q3 2026, filed 29 Oct 2026.